Literature DB >> 22270425

Progestin intrauterine device in an adolescent with grade 2 endometrial cancer.

Alaina J Brown1, Shannon N Westin, Russell R Broaddus, Kathleen Schmeler.   

Abstract

BACKGROUND: The treatment of endometrial cancer in young women who desire future fertility poses several challenges. Oral progestin and progestin-releasing intrauterine devices (IUDs) have been shown to result in regression of endometrial hyperplasia and grade 1 endometrioid endometrial carcinoma. However, limited data are available on the use of these methods in women with grade 2 disease. CASE: An 18-year-old nulliparous woman was diagnosed with a grade 2 endometrial adenocarcinoma. She desired future fertility and therefore underwent placement of a levonorgestrel-releasing IUD. The patient subsequently underwent endometrial sampling every 3 months and remained disease-free 13 months after initial IUD placement.
CONCLUSION: A progestin-releasing IUD may be a valid treatment option for grade 2 endometrial cancer in young women who desire to retain fertility.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22270425      PMCID: PMC3266511          DOI: 10.1097/AOG.0b013e318234d97c

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  10 in total

1.  Endometrial cancer.

Authors:  Kimberly K Leslie; Kristina W Thiel; Michael J Goodheart; Koen De Geest; Yichen Jia; Shujie Yang
Journal:  Obstet Gynecol Clin North Am       Date:  2012-06       Impact factor: 2.844

Review 2.  Catch it before it kills: progesterone, obesity, and the prevention of endometrial cancer.

Authors:  Matthew J Carlson; Kristina W Thiel; Shujie Yang; Kimberly K Leslie
Journal:  Discov Med       Date:  2012-09       Impact factor: 2.970

Review 3.  Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer.

Authors:  Jeong-Yeol Park; Joo-Hyun Nam
Journal:  Oncologist       Date:  2015-02-11

Review 4.  Preserving fertility in young patients with endometrial cancer: current perspectives.

Authors:  Eleftheria Kalogera; Sean C Dowdy; Jamie N Bakkum-Gamez
Journal:  Int J Womens Health       Date:  2014-07-29

5.  Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia.

Authors:  Weiwei Shan; Chao Wang; Zhenbo Zhang; Chao Gu; Chengcheng Ning; Xuezhen Luo; Qiongjie Zhou; Xiaojun Chen
Journal:  J Gynecol Oncol       Date:  2014-07-03       Impact factor: 4.401

6.  Progestin Intrauterine Devices and Metformin: Endometrial Hyperplasia and Early Stage Endometrial Cancer Medical Management.

Authors:  Oroma Nwanodi
Journal:  Healthcare (Basel)       Date:  2017-07-08

Review 7.  Fertility-Sparing Approach in Patients with Endometrioid Endometrial Cancer Grade 2 Stage IA (FIGO): A Qualitative Systematic Review.

Authors:  Pierluigi Giampaolino; Valeria Cafasso; Dominga Boccia; Mario Ascione; Antonio Mercorio; Francesco Viciglione; Mario Palumbo; Paolo Serafino; Cira Buonfantino; Maria Chiara De Angelis; Paolo Verrazzo; Giovanna Grasso; Giuseppe Gullo; Giuseppe Bifulco; Luigi Della Corte
Journal:  Biomed Res Int       Date:  2022-09-27       Impact factor: 3.246

8.  Endometrial adenocarcinoma in a 13-year-old girl.

Authors:  Sung Mee Kim; So Jin Shin; Jin Gon Bae; Kun Young Kwon; Jeong Ho Rhee
Journal:  Obstet Gynecol Sci       Date:  2016-03-16

9.  Dilatation and curettage is more accurate than endometrial aspiration biopsy in early-stage endometrial cancer patients treated with high dose oral progestin and levonorgestrel intrauterine system.

Authors:  Da Hee Kim; Seok Ju Seong; Mi Kyoung Kim; Hyo Sook Bae; Mi La Kim; Bo Seong Yun; Yong Wook Jung; Jeong Yun Shim
Journal:  J Gynecol Oncol       Date:  2016-08-02       Impact factor: 4.401

10.  Fertility-sparing treatment for intramucous, moderately differentiated, endometrioid endometrial cancer: a Gynecologic Cancer Inter-Group (GCIG) study.

Authors:  Francesca Falcone; Umberto Leone Roberti Maggiore; Violante Di Donato; Anna Myriam Perrone; Luigi Frigerio; Giuseppe Bifulco; Stephan Polterauer; Paolo Casadio; Gennaro Cormio; Valeria Masciullo; Mario Malzoni; Stefano Greggi
Journal:  J Gynecol Oncol       Date:  2020-09       Impact factor: 4.401

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.